Value-based health care: issues for pharmaceutical companies
Michael Lampert, Ropes & Gray health care partner, discusses issues facing pharmaceutical companies with the move towards value-based health care models.
Trending Legal Topics Similar Videos
Drug pricing initiatives during the Trump presidency
Tom Bulleit, Ropes & Gray health care partner, discusses the Trump Administration’s latest drug pricing initiatives.
Active nontransparent ETFs
Brian McCabe, Ropes & Gray asset management partner, discusses active nontransparent ETFs and the opportunities they offer to investors and asset managers of traditional mutual funds.
Trade secret litigation after the Defend Trade Secrets Act
Peter Brody, Ropes & Gray IP litigation partner, discusses the Defend Trade Secrets Act (DTSA) and how it has changed the trade secret litigation landscape since it was enacted in 2016.
Section 101: confusion over patentable subject matter
Matt Rizzolo, Ropes & Gray IP litigation partner, addresses the ongoing confusion over what constitutes patentable subject matter under Section 101 of the Patent Act.
False Claims Act: three years after Escobar
Kirsten Mayer, Ropes & Gray litigation partner, provides an update on the False Claims Act (FCA), three years after the Supreme Court’s decision on Universal Health Services v. U.S. ex rel. Escobar.
Behavioral sciences approach to risk management
Amanda Raad, co-chair of Ropes & Gray’s anti-corruption & international risk practice, discusses the new data-driven behavioral sciences approach to risk management.